Anticoagulation Clinic as Resident Teacher Gregory Raglow, MD Medical Director Jack Stuart, MD PGYII Michael Sty, MD PGYII Banner Good Samaritan FP Residency.

Slides:



Advertisements
Similar presentations
September 10, 2008 Medication Safety: Anticoagulation Management Carla S. Huber, ARNP MS Community Anticoagulation Therapy (CAT) Clinic Cedar Rapids, IA.
Advertisements

The Value of Medication Therapy Management Services
Warfarin Sodium (Anticoagulant) Therapy Training 03/10/2015.
POH/DMC UROLOGY Grand Round Conference Presented by: Spectrum Billing Technologies, LLC.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Improving care transitions at Harborview Medical Center Frederick M. Chen, MD, MPH Chief of Family Medicine Associate Professor, University of Washington.
24/7 Physician Access for Employees and their Families LOWERING COST IMPROVING HEALTH Phone Webcam .
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Clinical Pharmacy II Lobna Al Juffali,MSc Fall-2009.
AF and NOACs An UPDATE JULY 2014
Home visiting evaluation
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Increasing screening for osteoporosis Team /2013 Thanks to Georgia Carlson and N Topeka staff.
Care Coordination What is it? How Do We Get Started?
Managing Warfarin Drug Interactions: The Bayview Experience DAWN Users Group, November 2002 Charles H. Twilley, MBA, PharmD Johns Hopkins Bayview Medical.
Massachusetts General Hospital Anticoagulation Management Service Using Dawn AC to Support Safe Management of Anticoagulated Patients Lynn B. Oertel, MS,
Dr : Osama Badry Cardiology /Anticogaulation Coordinator Incharge of Anticoagulation Service AWH-HMC/Qatar.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Community Health Team Care Management Process PinnacleHealth Systems Don DeArmitt, M.D. Becky E. Zook RN, BSN, MS, CCP.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
TRAINING FOR ANTICOAGULATION IN PRIMARY CARE AND THE NEW GP CONTRACTS (Enhanced Services)
Bryan Bray, Pharm.D., CPP Chief Operating Officer Medication Management, LLC Vice President of Clinical Services Piedmont Pharmaceutical Care Network,
The Value of Medication Therapy Management Services.
Implementing universal Lynch Syndrome screening in a large healthcare system.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Coordinating Care Sierra Dulaney Lisa Fassett Morgan Little McKenzie McManus Summer Powell Jackie Richardson.
Clinical Pharmacy Part 2
Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Asthma Management and the Allergist: Better Outcomes at Lower Cost.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
Resident Self Assessment Where do you fall on the continuum for each of the following? Please make an “X” on each line then date it: History Novice Advanced.
1 Syd Stewart and Claire Alexander November 2003 Patient Compliance and Benchmarking.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.
MTM Medication Therapy Management. What is Medication Therapy Management? From 1996 to 2006, the number of prescription medications dispensed increased.
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal.
Group Visits for Diabetes: An improved model for care Jessica McIntyre M.D.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory.
Medical Documentation CHAPTER 17. Purposes of Documentation  Communication  Most patients receive care from more than one source  Allows all health.
Pharmacy Health Information Technology Collaborative Presenter: Shelly Spiro RPh, FASCP Pharmacy HIT Collaborative, Executive Director.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.
Management of Patients on Chronic Oral Anticoagulant Therapy
Cheryl Schraeder, RN, PhD, FAAN Health Systems Research Center
Warfarin pretest Joshua Steinberg MD.
Mary McDonough RN Jeff Aalberg MD October 28, 2006 NESTFM
Heart Valve Thrombosis & Neuro-Outcomes
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Clinical Pharmacy II.
Anticoagulation in Atrial Fibrillation
Aug, 2016.
Click here for title Click here for subtitle
Standing Orders as a System Change
Warfarin Prescribing.
Selecting NOACs for High-Risk Patients
The first screen used is designed to document symptom pursuit and review the complications of anticoagulation therapy. In addition this screen is where.
GHS Outpatient Enoxaparin Program
Home visiting evaluation
Health Care Information Systems
Patient education for the growing Coumadin population.
Presentation transcript:

Anticoagulation Clinic as Resident Teacher Gregory Raglow, MD Medical Director Jack Stuart, MD PGYII Michael Sty, MD PGYII Banner Good Samaritan FP Residency

Objectives Rationale and Set-up Demonstration of CoumaCare Software program Cases to teach: –Warfarin management –Chronic Disease management principles –Practice Innovation –Practice Based Learning and Improvement QA Project findings Resources for initiating this at your program

Objectives Oh, and show off our beautiful state

Rationale JAMA article documenting improved care Support of Nursing and Practice Management Resident Champion Team approach Opportunity to demonstrate practice innovation (FOFM)

Clinic Set-up Group visit (not mandatory) Referral form Principles –Maintain PCP relationship –Dosing adjustment only –Advise for procedures Algorithm Computer-based tracking Workflow

Group visit More time to teach –Why you’re on warfarin, benefits, risks, side effects –Effects of diet, other drugs –How clinic works PowerPoint presentation Time for questions Billed as Templated visit form

Invitation Letter

Visit Template

Diet Guidelines

Medication Guidelines Inform clinic personnel when meds change Always ask doctor if warfarin is affected when meds added May need closer monitoring

Procedures Schedule appointment 2 weeks in advance to discuss warfarin therapy Often we have to discuss with consultants Familiarity with guidelines varies

Referral form for clinicians Agreement about management principles Gather data about patient

Principles PCP relationship maintained Clinic personnel can serve as resource for decisions Clinic manages dosing to achieve goal INR set by PCP Pts advised to see PCP prior to procedures ACCP Guidelines and Algorithm

Workflow Draws on Tuesdays (standing orders) Weekly dosing Single tablet strength (usually 5 mg) Review labs the next day Nurse manager calls patient Algorithm Abnormals

Workflow Nurse Manager Physician Lab Tech

Computer tracking system

Algorithm

Case 1 High

Humphrey Peak 67 y.o. Male with AF, HTN INR = 3.3 Target Current dose 5 mg/day –(35 mg/wk) Previous INRs 2.8, 2.5 What to do?

Marginal high Marginal if INR <0.5 off target Wait until 2 of 3 are off before changing dose Avoids chasing your tail

Marginal high 2 of 3 marginally high Adjust weekly dose based on chart

Dosage adjustment DaySunMonTueWedThuFriSat Tablet Size Number New Number /2 Weekly dose 35  30 mg

Case 2 Higher and higher

Ima Bleedin 55 yo F 3 months S/P DVT INR = 7.8 Weekly dose 30 What to do?

Anticoagulant Questions

Ima Bleedin Pt was on ABX 2 days left Bleeding Gums

ACCP Guidelines for High INR

ACCP Guidelines Describes strategies for high INR Based on INR value and presence of bleeding Hold Warfarin Give Vit K if bleeding or hi risk Green Tea effective

Case 3 ‘Twas the Night before Christmas… Nurse Kim knocks on my door

Rudy Rednose 37 yo female, Hx DVT INR of 8.2 Unable to find patient using all numbers What to do?

Rudy Rednose Returned Monday after holiday C/o epistaxis Held dose, added green tea Hmmm, can we prevent this?

Residents strategized Need all contact numbers Need cell phones INSTRUCTED PTS TO CALL IF NO CONTACT W/IN 48 hrs of lab draw Called all patients on list Added this to Group visit topics

Competencies Practice-based Learning and Improvement Systems-based practice

Case 4 And it goes on and on and on and on….

Ruth Sixtysix Received INR of 4.2 Reviewed chart 33 yo female Hx DVT after leg Fx with casting 18 Months Ago

Ruth Sixtysix No other risk factors ACCP Guidelines on length of therapy Should have stopped

What went wrong? PCP had determined length of therapy No stop date entered in computer

Strategies Reviewed all computer pt records to see if other pts need a stop date If unclear, then sent letter to PCPs and followed up on data

Competencies Another example of Practice-based Learning and improvement Access to computerized data is example of practice innovation Use of IT as promoted by FOFM Group visits Chronic Disease Management

Case 5 Up and down

Grant Canyon

Narrow Therapeutic Window

Tighter control Use of Coumadin Brand

Computer benefits Graphic data easier to assess List of names readily available On server, so accessible from many locations

Case 6 Dental Procedure

Call from dentist What to do about warfarin patient? Many specialists uncomfortable Need help and information Anticoag clinic personnel serve as resource

Other Procedures GI procedures Orthopedic Surgery Other surgery

ACCP Guidelines

ACCP Guidelines for anticoagulation during procedures

Anticoagulation Clinic: A Residents Perspective

Creation of the Coumadin Clinic Project started by Dr. Lee to improve practice management. Patients recruited through PCP referral, invitation of patients known to be on Coumadin, review of billing codes Design modified based on a Coumadin Clinic established in the Internal Medicine Department

Review of Evidence 1 “Comparing the Quality of Oral Anticoagulant Management by Anticoagulation Clinics and by Family Physicians: a RCT” Wilson, et al. CMAJ 2003;169(4): Primary Outcome: proportion of time INR in an expanded therapeutic range Secondary Outcome: rates of thromboembolic and hemorrhagic events

Review of Evidence 1 Significant benefit of time spent in expanded therapeutic window with AC Management (82% vs. 76%) Fewer patients with INR 5.0 Less blood draws with AC care Overall patient satisfaction higher.

Review of Evidence 2 Am J Med. 2002; 113: Randomized trial involving patients 65 years and older with afib. Compared proportion of time in a therapeutic window with baseline management against anticoagulation clinic management.

Review of Evidence 2 No significant improvement time spent inside a therapeutic window. Control group (baseline: 47.7% follow up: 55.6%) Intervention group (baseline: 49.1% follow up: 52.3%) Event rates were not statistically significant between groups.

Arch Inern Med. 1998; 158: Review of Evidence 3 “Comparison of an Anticoagulation Clinic with Usual Medical Care” Chiquette et al –Compared “UMC” to “AC” –Cohort study –Newly anticoagulated patients –145 in UMC –183 in AC

Review of Evidence 3 Lower range –Fewer INR’s >5 (7% vs 14.7%) –More time in range (40% vs 37%) Higher range –More INR’s in range (50% vs 35%) –Fewer INR’s <2 (13% vs 23.8%) Fewer significant complications Savings of $162,058 per 100 patient years

Effective Clinical Practice Jul-Aug; 3 (4): Review of Evidence 4 “Complications of Warfarin Therapy: causes, costs, and the role of anticoagulation clinic” Hamby et al –Cohort study –306 patients followed –278 by VA AC, 28 by VA physicians –Events reviewed –Determined if preventable Bleeding (INR >5) Thrombosis (INR <2)

Review of Evidence 4 12 Total events occurred 8 not enrolled in AC Relative Risk 20 (95% CI, 6.4 to 61.8) An estimated $2300 per patient in costs for complications

7 th ACCP Conference Guidelines

Management should be done in a systematic and coordinated fashion. Essential features of management include: –patient education –systematic INR testing –tracking of data –adequate follow up –appropriate communication with patients regarding dosing decisions

7 th ACCP Conference Guidelines Bottom Line: No specific recommendation exists as to the need for establishment of a AMS. More data is needed.

QA Study—How are we doing? Informal study performed at GSRMC FPC Compared results before and after the start of the warfarin clinic Outcome measures –INR values in and out of range –Months in therapeutic range, out of range or not measured

Demographics Anticoagulation Clinic –32 females, 20 males –12 atrial fibrillation –4 CVA/Small vessel disease –2 Lupus anticoagulant –9 Pulmonary embolism –5 Mechanical heart valves –4 multiple –5 other

Demographics Usual Care –15 females, 17 males –10 atrial fibrillation –6 DVT –5 Pulmonary embolism –5 Mechanical heart valves –4 multiple –2 other

QA Study—How are we doing? INR Percentages –In therapeutic range –Marginal range (+/- 0.5) –Out of range –Months without INR values

QA Study—How are we doing? How did we do before?

QA Study—How are we doing?

Results

Critical events Before2 After start of Anticoag clinic0

Advantages of AC Improved patient education, tracking of results, and communication Improved patient continuity and follow up in a system with high physician turnover and limited physician experience Decreased adverse events

Advantages of AC Improved resident education –Intern curriculum –Noon conference curriculum –PCP involvement in decision making Platform for teaching practice management systems

Future Directions In-office testing Charge for some of the work

Point-of-Care Anticoagulation Devices Provide an INR result within 3 minutes of administering a drop of whole blood. Advantage: convenient, possible increased compliance, greater time spent in the therapeutic window, quicker lab return, billing Disadvantage: proper selection of patients, cost ($ for machine; $6-10 for cuvette)

Point-of-Care Anticoagulation Devices Am J Cardiovasc Drugs 2001; 1(4): Reviewed benefits and implications for clinical practice Most studies show only modest benefit in terms of time in therapeutic window. One study demonstrates decreased thromboembolic and bleeding events over a 2 year period. (13.5 vs. 9.5%)

Anticoagulation Devices: Candidates 1.Require long term or life long therapy 2.Have no functional impairments 3.Appropriate cognitive abilities and willingness to manage own healthcare 4.Have appropriate funds or insurance

Anticoagulation Devices: Billing Point-of-Care testing may allow billing of a visit at our facility Obtain brief history and physical exam if needed. MDM based on INR value. Lab assessment of PT/INR (CPT: 85610) Long-term management of oral anticoagulants (V58.61)

Main Points

Anticoag clinics Result in improved care Can be used to teach important competencies Create a self-learning and motivating environment Practice innovation

Discussion

Resources All materials Tracking software ACCP Guidelines Algorithm Templates PowerPoint presentations